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a b s t r a c t
Navigate PD was an educational program established to supplement existing guidelines and provide
recommendations on the management of Parkinson's disease (PD) refractory to oral/transdermal ther-
apies. It involved 103 experts from 13 countries overseen by an International Steering Committee (ISC) of
13 movement disorder specialists. The ISC identiﬁed 71 clinical questions important for device-aided
management of PD. Fifty-six experts responded to a web-based survey, rating 15 questions as ‘criti-
cally important;’ these were reﬁned to 10 questions by the ISC to be addressed through available evi-
dence and expert opinion. Draft guidance was presented at international/national meetings and revised
based on feedback. Key take-home points are:
 Patients requiring levodopa >5 times daily who have severe, troublesome ‘off’ periods (>1e2 h/day)
despite optimal oral/transdermal levodopa or non-levodopa-based therapies should be referred for
specialist assessment even if disease duration is <4 years.
 Cognitive decline related to non-motor ﬂuctuations is an indication for device-aided therapies. If
cognitive impairment is mild, use deep brain stimulation (DBS) with caution. For patients who have
cognitive impairment or dementia, intrajejunal levodopa infusion is considered as both therapeutic and
palliative in some countries. Falls are linked to cognitive decline and are likely to become more frequent
with device-aided therapies.
* Corresponding author. Department of Neurology, Skane University Hospital, SE-
221 85 Lund, Sweden.
E-mail addresses: per.odin@med.lu.se, per.odin@klinikum-bremerhaven.de
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 Insufﬁcient control of motor complications (or drug-resistant tremor in the case of DBS) are in-
dications for device-aided therapies. Levodopa-carbidopa intestinal gel infusions or subcutaneous
apomorphine pumpmay be considered for patients aged >70 years who have mild or moderate cognitive
impairment, severe depression or other contraindications to DBS.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Parkinson's disease (PD) is characterized by motor symptoms,
such as bradykinesia, rigidity, tremor and postural instability. In its
early stages, treatment with oral dopaminergic therapies is usually
effective; however, as the motor disease progresses these therapies
no longer provide adequate control of symptoms which range from
motor and non-motor ﬂuctuations to dyskinesias. At this stage, it is
important to ensure timely referral of patients to a movement
disorder specialist before deterioration in quality of life (QoL) and
development of complications of advancing disease [1,2]. It may be
appropriate to consider device-aided treatments when motor
ﬂuctuations become refractory to adjustments in oral/transdermal
medication, and when these adjustments are typically complicated
by the emergence (or worsening) of dyskinesias [2].
Three device-aided treatments are available:
 subcutaneous (SC) apomorphine pump [3];
 levodopa-carbidopa intestinal gel (LCIG) [4] infusions [5,6];
 deep brain stimulation (DBS) [7].
Alongside motor symptoms, people with PD also experience
non-motor symptoms (NMS) such as: pain, drooling; choking/
swallowing difﬁculties; constipation; bladder dysfunction; cogni-
tive impairment; hallucinations; depression/anxiety; sexual
dysfunction; insomnia, which occur from disease onset [8]. Non-
motor symptoms contribute to severe disability, impaired QoL,
and institutionalization [9], and can be more troublesome and
disabling for the patient than motor complications [10]. Recent
work suggests some NMS are treatable using device-aided thera-
pies [11,12] since they are often dopaminergic in origin. Further-
more, some NMS speciﬁcally complicate motor ﬂuctuations, and
are treatable by strategies that attenuate ﬂuctuations [13].
Current guidelines provide recommendations based on ran-
domized placebo-controlled studies providing level 1 evidence of
treatment. Such evidence is often not available for a range of non-
motor issues as well as somemotor phenomena. This leads to a lack
of pragmatic real-life instruction on how to treat patients with
device-aided therapies when oral/transdermal medications no
longer effectively control their symptoms [14,15]. Despite multiple
evidence-based guidelines, there remain clear gaps in knowledge,
which, in clinical practice, are addressed through expert judgment
and experience.
To supplement current clinical guidelines, a pan-European
educational program, ‘Navigate PD’, was established to identify
the key unresolved issues in the management of PD refractory to
oral/transdermal therapies and explore questions commonly raised
by clinicians about the optimal use of device-aided treatment. Here
we propose approaches for the management of clinically important
unresolved issues in PD based on the experience and expert
opinion of over 100 experts in the ﬁeld of PD/neurology.
A total of 103 experts from 13 countries worldwide participated
in the Navigate PD program (Working Group members excluding
authors of this paper are listed in Acknowledgments). Each country
had its own National Steering Committee and the program was
overseen by an International Steering Committee (ISC) of 13
specialists from Europe and chaired by two authors of this paper
(PO and KRC). The lead authors were contacted and suggested the
Steering Committee. AbbVie then contacted a leading MD specialist
in each of the participating countries, who could then suggest the
specialists participating from each country. The main criteria for
participation was to be an internationally recognized movement
disorder specialist with well-documented experience with
advanced PD therapies.
The objectives of the program were:
 to identify and address the most important questions relating to
device-aided management of PD;
 to provide practical answers based on available evidence and
the clinical experience of participants; and
 to develop pan-European guidance for PD management beyond
oral/transdermal therapy that clearly deﬁnes the patient and
treatment choices available.
The multi-step program took place between April 2012 and July
2013 and involved numerous international and national meetings
attended by neurologists, geriatricians and MD specialists repre-
senting many countries. The process is outlined in Fig. 1.
The ISC identiﬁed areas of clinical focus and developed 71 key
questions (Appendix 1), which were ranked in a web-based sur-
vey by the experts. Based on this ranking, the ISC prioritized
questions via informal debate, then prepared draft guidance for
each based on available evidence from literature reviews com-
bined with expert opinion where evidence gaps existed. The draft
guidance was presented and discussed at national and interna-
tional meetings and revised based on the feedback obtained. This
was not a formal consensus or Delphi process; the program aimed
to achieve answers on which all participants had reached broad
agreement.
Fifty-six completed web-based prioritization questionnaires
were returned. Of 71 questions, 15 were rated as ‘critically impor-
tant’ by at least one-quarter of respondents. These were further
reﬁned by the ISC to 10 questions to be addressed through litera-
ture search and expert opinion.
2. Practical guidance on device-aided management of PD
derived from discussions of navigate PD
2.1. How do I recognize and refer for specialist assessment a patient
in whom the dosage and adjustment of oral/transdermal therapies
cannot further improve mobility and quality of life?
Non-invasive therapies may be judged insufﬁcient when QoL
becomes inadequate due to motor ﬂuctuations with or without
dyskinesias, and the clinician and patient agree that non-invasive
therapy alone is no longer effective. Adequate trial of non-
invasive therapies includes levodopa and, unless contraindicated,
dopamine agonists, monoamine oxidase-B inhibitors and catechol-
O-methyltransferase inhibitors. Broadly, referral to a specialist
should be considered if levodopa is required 5 times daily,
although the number of doses is not relevant if tolerated by the
patient and an adequate reduction in ‘off’ time is achieved.
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Individuals with >1e2 h of ‘off’ time during the awake part of the
day despite optimized oral/transdermal medical management
should be considered candidates for device-based therapies. The
severity and quality of a patient's ‘off’ periods are equally important.
Some patients withmarked ‘off’ symptoms should be considered for
referral even if their overall ‘off’ duration appears acceptable. If
symptoms continue to be refractory or intolerable side-effects
develop, as determined by patient feedback, such as the Patient
Diary (Appendix 2), oral/transdermal management is inadequate
and further medication adjustment is unlikely to be beneﬁcial.
Motor ﬂuctuations accompanied by troublesome dyskinesias
not controlled by addition of amantadine (100e400 mg/day, if
available), despite multiple attempts to achieve a patient-
acceptable response to non-invasive or transdermal therapies are
usually considered an indication for referral for device-aided
therapy.
If patientsmeet the above criteria, referral should be considered,
including for patients with a disease duration <4 years.
2.2. What is the relevance of cognitive dysfunction, postural
instability and falls in the decision to move to device-aided therapy?
Signiﬁcant cognitive impairment and postural instability are
features of advancing PD characterized by increasing
levodopa-resistant symptoms and acceleratedmotor disability [16].
Riskebeneﬁt analysis of device-aided therapy should consider
possible motor improvement and individual risks, as well as ex-
pected disease progression with or without device-aided treat-
ment. Cognitive decline, falls and gait problems such as freezing
may counteract beneﬁcial responses. However, cognitive issues
such as clouding of consciousness, concentration impairment as a
manifestation of non-motor ﬂuctuation and freezing may occur
during ‘off’ periods and should be treatable by device-aided ther-
apies [13].
Cognitive assessment should be conducted ideally at ‘on’ and
‘off’ stages before initiating device-aided therapy, recognizing that
even marked cognitive impairment may be a consequence of a
patient's current treatment.
Deep brain stimulation of the subthalamic nucleus (STN-DBS) is
generally well tolerated in patients with normal age-related
cognition. Caution is advised in patients suggestive of imminent
or apparent cognitive decline [17]. Patients exhibiting symptomatic
cognitive deﬁcits should be excluded because experience has
shown a risk of cognitive worsening postoperatively in these pa-
tients [18]. DBS of the globus pallidus pars interna (GPi-DBS), which
is associatedwith fewer cognitive risks, may be suitable for patients
with mild cognitive impairment [19,20], although this has recently
been challenged [21].
Fig. 1. Overview of the process used by the Navigate PD program for developing practical guidance on the device-aided management of Parkinson's disease.
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The effects of LCIG infusions or SC apomorphine infusion on
cognition are inconclusive [17,22,23]. As with any dopaminergic
treatment, an increased risk of confusional states or hallucinations
in cognitively impaired patients can be expected, particularly with
a potent dopamine agonist treatment, which should be balanced
against potential motor beneﬁts. Nevertheless, infusion therapies
can be effective in selected patients with cognitive dysfunction. The
risk of cognitive decline or neuropsychiatric complications may be
greater with SC apomorphine than LCIG infusion. A recent
comparative study of apomorphine versus intrajejunal levodopa
infusion (IJLI) therapy did not report worsening of hallucinations at
6-month follow-up [24].
LCIG or SC apomorphine infusion can be given in patients with
mild cognitive impairment if adequate caregiver support is avail-
able. In moderate dementia, LCIG may be considered on an indi-
vidual basis. In patients with cognitive impairment, the decision to
implement device-aided treatment should bemade by amovement
disorder specialist in consultation with the patient and caregiver,
with consideration given to the balance of cognitive impairment
and caregiver support.
Device-aided therapy should be considered if a patient's bal-
ance/gait responds well to increases in oral levodopa and the pa-
tient is stable in the ‘off’ state. Patients with balance problems due
to dyskinesias or levodopa-responsive postural instability may
improvewith all three device-aided treatments [23,25,26]. Beneﬁts
in gait and balance after STN-DBS may be greater and more sus-
tained in younger patients, and are closely linked to the levodopa-
responsiveness of axial motor symptoms before surgery [17]. In
elderly patients (biological age >70e75 years), STN-DBS does not
match the beneﬁts of levodopa on axial symptoms, leading to
increased gait or balance problems and more frequent falls after
surgery [17,27]. The risk of falling should be considered in older
patients. The beneﬁts of DBS of the pedunculopontine nucleus area
remain to be clariﬁed.
Subcutaneous apomorphine and LCIG may have positive effects
on levodopa-sensitive gait and balance problems or on dyskinesia-
related problems [17]. Patients and caregivers should be made
aware that gait and balance problems unresponsive to levodopa are
less likely to improve on infusion therapy.
2.3. What is the efﬁcacy of each device-aided treatment on motor
ﬂuctuations and dyskinesias?
Evidence-based data are limited for device-aided treatments in
PD. Randomized controlled trials often exclude patients who reﬂect
real-world populations based on their age and stage of disease. To
achieve maximal improvement in ‘off’ and ‘on’ time without dys-
kinesias, physicians may choose any of the three device-related
therapies. Although no randomized controlled trials directly
compare device-aided therapies, data from separate studies
including open-label observational studies show:
1. STN-DBS achieves improvements in motor ﬂuctuations,
reducing ‘off’ time by 25e68%, thus the levodopa equivalent
dose can be reduced by 31e68% and dyskinesias reduced by
40e60% [28];
2. SC apomorphine infusion achieves improvements in motor
ﬂuctuations and time with dyskinesias by 50e85% and 43e64%,
respectively [29e40];
3. LCIG infusions achieve improvements in motor ﬂuctuations and
time with dyskinesias of 49e64% and 47e59%, respectively
[4,41].
In summary, the effects on ‘off’ ﬂuctuations are comparable
across the device-aided therapies, although for SC apomorphine,
only data from uncontrolled studies are available. All three thera-
pies have an effect on dyskinesias, but these effects are best
documented with DBS.
2.4. What is the efﬁcacy of each device-aided treatment on non-
motor symptoms?
Non-motor symptoms in advanced PD can be challenging to
treat. With the exception of dementia, hallucinations and
depression, few clinical studies have been speciﬁcally designed to
assess other relevant NMS such as apathy, sleep dysfunctions, pain
and fatigue. The efﬁcacy of device-related therapies on NMS is
supported largely by anecdotal clinical evidence, thus NMS
without ﬂuctuations should not be considered as a speciﬁc indi-
cation for device-aided therapies. However, clinical experience
and some clinical data suggest that NMS, particularly those with a
dopaminergic basis, respond [42]. Therefore NMS might be
considered for helping select the type of device-aided therapy in
individual cases. Examples of studies in which device-aided
therapies have had beneﬁcial effects on NMS are documented in
Table 1.
2.5. What are the adverse events and complications of each device-
aided treatment?
The following safety information has come from selected
available studies. Study designs, patient populations and meth-
odology for safety monitoring vary so the prevalence of compli-
cations and adverse events (AEs) cannot be compared between
treatments.
Complications and AEs related to DBS may occur during sur-
gery, in the immediate postoperative period and upon chronic
stimulation. The rate and frequency of the most common com-
plications are shown in Table 2. When selecting patients for DBS,
clinicians must consider the possible and likely AE proﬁle on a
case-by-case basis. The choice of DBS target may depend on in-
dividual features, particularly age or mild behavioral changes.
The psychiatric status of the patient should be assessed because
there may be a risk for developing apathy post DBS. Depression
and suicidal risk should be considered in the presence of previ-
ous psychiatric history. Balance and dysarthria may worsen and
must also be considered. It is important to ensure that the pa-
tient is operated on at a center with appropriate surgical
expertise and adequate facilities for follow-up and long-term
care.
Complications and AEs related to SC apomorphine may occur
during the initiation of treatment or ongoing treatment, and can
be related to the device or the drug. Limited published data are
available on the safety and tolerability of continuous SC
apomorphine infusion. In general, available data are derived
from case series and case reports [31,33,34,37,38,41,63,64]. The
rate and frequency of the most common complications are
shown in Table 3. To minimize the risk of complications, pa-
tients, caregivers and physicians should ensure optimal care of
skin problems, use correct, up-to-date and sterile cannulas,
conduct regular blood checks to identify potential autoimmune
hemolytic anemia (exceedingly rare) and monitor patients for
possible development of dopamine agonist-related behavioral
problems.
Complications and AEs related to LCIG infusions may occur
during surgical implantation or use of the device, and can be
related to the device or the drug. Limited published long-term
data are available on the safety and tolerability [49]. The rate
and frequency of the most common complications are shown
in Table 4. To minimize the risk of complications, an
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experienced gastroenterologist who is familiar with the infu-
sion system used should be involved. Close collaboration be-
tween the neurologist and gastroenterologist is essential.
Patients should be monitored for peripheral neuropathy,
weight loss and vitamin B12 status.
2.6. Which patient should not be considered for each or any device-
aided therapy?
Relative and absolute contraindications to device-aided
therapies are shown in Table 5. Lack of a response to levodopa
Table 2
The rate and frequency of the most common adverse events and complications associated with deep brain stimulation.
Relatively frequent (10%) Infrequent (<10% to 5%) Rare (<5%)
Surgical complications
Death (within 30 days postoperatively) 0e2.6%
Symptomatic intracerebral hematoma 0e1.3%
Asymptomatic intracerebral hematoma 0e2.6%
Postoperative confusion (mild to moderate) 2.7e5.1%
Pulmonary embolism 0e1.1%
Urinary retention 0e2.2%
Device-related complications
Infection at hardware site 2.6e9%
Extension cable discomfort 0e2.6%
Subcutaneous seroma 0e5.1%
Skin erosion 0e5.1%
Hardware dislocation/fracture 0e3.2%
Technical device failure 0e2.4%
Other post-surgical AEs (related to stimulation or to PD)
Anxiety 0e4.8%
Apathy 0e4.8%
Balance and gait problems 8.2e13.7%
Cognitive disturbances 0.8e5.1%
Daytime sleepiness 0e4.0%
Depression 4.8e16.9%
Dysarthria 5.8e10.3%
Dyskinesias increased 0.8e25.6%
Dystonia 0e6.6%
Falls 1.6e7.1%
Fluctuations 0e8.8%
Fractures from falls 0e1.3%
Freezing/worsening of mobility 5.8e32%
Pain 0e15.3%
Psychosis 0e5.1%
Seizures 0e1.1%
Suicide attempt 0e1.6%
Suicide committed (chronic stimulation) 0e1.3%
Weight change 0e12%
*Based on four large (>50 patients) randomized controlled trials comparing DBS with best medical management in Parkinson's disease [59e62]. Note that patients collectives
differ in the studies evaluated (grade of advancement of PD), follow-up times differ, and it is not possible to differentiate inmany reports whether side effects were transient or
permanent, nor whether they were mild, moderate or severe.
AE, adverse event; PD, Parkinson's disease.
Table 1
Clinical evidence showing beneﬁcial effects of device-aided therapies on non-motor symptoms (NMS).
 In a small case series, STN-DBS did not have notable immediate effects on NMS, but showed beneﬁt on depression, anxiety and fatigue in some patients over time [43].
 A multicenter European comparative cohort study evaluating the motor and non-motor effects of SC apomorphine infusion and LCIG infusion found that both treat-
ments signiﬁcantly improved NMS from baseline [44].
 SC apomorphine has been shown to improve NMS in a small comparative study with best oral and transdermal medical therapy, with effects most pronounced on sleep/
fatigue, mood/apathy and excessive sweating [45]. Although there are few data, there is a suggestion of some beneﬁt on urinary symptoms.
 LCIG infusion has been shown to signiﬁcantly improve several non-motor symptom domains, including cardiovascular, sleep/fatigue, gastrointestinal, urinary, and
sexual functioning [17,46e48]. It may also have a beneﬁcial effect on depressive symptoms, delusions and impulse control disorders (ICDs) [47,49]. LCIG probably
decreases the frequency of spontaneous night-time leg movements, however, data are lacking.
 An open-label, prospective, multicenter, 6 month study comparing 44 patients on LCIG infusion and 43 patients on apomorphine infusion, sleep/fatigue, gastrointestinal,
urinary and sexual dimensions of the NMS scale showed signiﬁcantly higher improvement with LCIG infusion compared with apomorphine infusion. Furthermore, LCIG
improved QoL and NMS in 75% of patients; apomorphine infusion improves QoL and NMS in 75% and 40% of patients, respectively [24].
 ‘Off’-related pain has been shown to respond to STN-DBS in a 2-year follow up study [50]. It responds also to GPi-DBS, which has been demonstrated at 1-year follow-up
[51]. There is evidence from uncontrolled studies showing an improvement in pain with LCIG infusion and with apomorphine infusion.
 Small case series have suggested that objective and subjective sleep symptoms may improve following DBS [17,52e55], LCIG infusion [46,47,56], and apomorphine
infusion [45].
 In patients with severe impulse control disorders, DBS may be a useable treatment option [57]. However, there are conﬂicting data on the effect of DBS in patients with
impulse control disorders or dopaminergic dysregulation syndrome, with aggravation in some and marked improvements in others, if dopaminergic medication
withdrawal was tolerated [17]. LCIG infusion may also be effective as it allows tapering or withdrawal of oral dopamine agonists [58].
 An observational, 2-year follow-up study of 19 patients receiving LCIG infusion found that LCIG infusion confers a low risk of developing impulse control disorders and
may be useful in the management of refractory impulse control disorder (A Todorova; abstract presented at MDS' ICDs in PD conference, Oct 2012).
 In a survey in which 41 patients receiving SC apomorphine were screened for development or attenuation of impulse control disorder, SC apomorphine was associated
with a 9.7% risk of development of impulse control disorder (A Todorova; abstract presented at MDPD, Apr 2013).
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(with the exception of rest tremor for DBS) is an absolute contra-
indication for all device-aided therapies and non-compliance with
non-invasive therapies is considered to be a risk factor, although
not an absolute contraindication.
2.7. What information about each device-aided therapy should be
conveyed to a patient and caregiver?
Patients and caregivers must be committed to the device-aided
treatment and aware that it is not disease-modifying and that the
patient must endure an operation (for DBS and LCIG infusion) and
numerous follow-up visits.
The clinician must manage the expectations of the patient and
caregiver in terms of QoL and ability to perform activities of daily
living, ensuring an understanding of realistic treatment goals in
terms of short- and long-term outcomes. Patients and caregivers
should understand that improvements will be an increase in ‘on’
time duration (decrease in ‘off’ time), but the level of symptom
improvement will not be greater than that achieved when at their
most responsive to oral therapies, except possibly for reduced
dyskinesia (and with the exception of tremor in the case of DBS).
Some symptoms may not improve with device-aided therapy
(mainly NMS, but also motor symptoms, such as instability, falls or
freezing when present during ‘on’).
Each device-aided therapy can be associated with side-effects
and complications, and device malfunction/failure. Patients
should be advised on how to manage the device after discharge,
troubleshoot potential problems and prepare medication in order
to make an informed decision on whether they or their caregiver
can manage the treatment. In many countries, validated patient-
related outcome tools are likely to be recommended for routine
use in advanced therapies [67].
The information given to the patient and caregiver should be
patient-speciﬁc, i.e. physicians should only discuss in detail
potential treatment options available for that patient. However,
patients should have access to all information so they feel fully
informed. Patients and caregivers can be directed to reliable web-
sites, such as those provided by PD patient associations. Further
guidance on providing information to patients/caregivers is given
in Appendix III.
2.8. When is the right time to inform a patient about device-aided
treatment options and how should they be informed about the
treatments? What tools and consultation techniques should be used
when communicating information to patients?
Device-aided therapy options should be discussed before pa-
tients become candidates for the devices so they can be reassured
that there are treatment options for the future. Patients at high risk
for developing motor complications, particularly young-onset pa-
tients, should be informed early on about the availability of device-
aided therapies.
If possible, balanced information should be given by a physician
with personal experience of all three device-aided therapies and
aware of the possibility of bias based on their own experience and
preference. Information on all device-aided therapies should be
provided, including brief information on any not indicated or rec-
ommended for an individual patient to reassure them that they
have received all available information. The physician should also
give an opinion on themost appropriate treatment for an individual
patient.
Discussing device-aided treatments is a stepwise process, which
may occur over several years:
 ﬁrst, the idea should be introduced;
 at later visits, greater detail should be provided;
 ﬁnally, full information should be given and the patient's con-
sent obtained.
Communication tools should be standardized and unbiased e.g.
literature from patient associations and medical professional soci-
eties, but the information also needs to be individualized, e.g. based
upon a patient's age or caregiver's ability. A patient may need to be
told why a certain treatment is inappropriate for him/her, e.g. DBS
in the elderly patient.
Depending on a patient's level of interest, the use of videos or
directing them to websites may be appropriate. Talking to a
specialist nurse or other health professional who deals with the
practical aspects is helpful and recommended, as may be direct
demonstration of the device(s) under consideration. In the case of
pump treatments, involving district nurses or other professional
caregivers to help with setting up the pump, e.g. each morning,
should be explored and discussed when appropriate. For some
Table 3
The rate and frequency of the most common adverse events and complications associated with subcutaneous apomorphine.
Relatively frequent (10%) Infrequent (<10% to 5%) Rare (<5%)
Administration/device-related complications
Needle/injection-site pain 35.0% [35]
Apomorphine-related complications
Nodules 41e100.0% [23,32,36,65]
Weight gain 60.0% [35]
Neuropsychiatric AEs 36.4e44.0% [32,36]
Daytime somnolence 31.0% [35]
Nausea 4.0e18.2% [32,36]
Orthostatic hypertension 16.0% [36]
Mild sedation 13.6% [32]
Coombs antiglobulin positive 12.5% [35]
Hemolytic anemia 0.6e9.1% [35,23,32]
Urinary urgency 8.0% [36]
Abscess 1.6e4.0% [35,36]
Necrosis 0e4.0% [36,65]
Hyperlibidinous effect 4.0% [36]
Diarrhea 4.0% [36]
AE, adverse event.
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patients, an opportunity to interact directly with other patients
already on a device-aided treatment, e.g. at patient support groups,
may be particularly helpful. The physician should encourage
involvement in PD patient associations to help patients become
better informed.
2.9. How do I manage non-invasive therapy in a patient on device-
aided treatment?
During the ﬁrst phase of treatment (3 months after initiation),
the movement disorder specialist is responsible for adjustments to
both the device-aided treatment and non-invasive therapies,
ensuring that the referring neurologist is fully informed of all
treatment decisions. Access to patient records is essential to un-
derstand previous treatments and doses and the parameters for
which the device-aided therapy has been introduced.
Anti-PD treatment should be restarted after DBS to relieve
discomfort and limit the risk of acute dopaminergic withdrawal
and neuroleptic malignant syndrome. The aim is to balance stim-
ulation effects and concomitant medication. Dopaminergic medi-
cation is decreased to reduce the risk of dyskinesia, sedation,
excessive daytime sleepiness and confusion. Aggressive medication
reductions should be avoided because they may lead to the re-
emergence of motor and NMS.
Subcutaneous apomorphine can be considered as monotherapy
or as an add-on to levodopa depending on the patient's tolerance of
Table 4
The rate and frequency of the most common serious adverse events, adverse events and complications associated with levodopa-carbidopa intestinal gel infusion.
Relatively frequent (10%) Infrequent (<10% to 5%) Rare (<5%)
Surgical/device-related complications
Complication of device insertion 21.4e56.6% [4,41,66] 6.8% [41]
Procedural pain 17.7e29.7% [4,41,66] 0.8% [66]
Post-operative wound infection 10.4e21.0a% [4,41,66]
Incision site erythema 9.4e18.9% [4,41,66]
Medical device site reaction 38.0a% [66]
Device dislocation 34.7a% [66] 1.6% [41]
Device occlusion 29.4a% [66]
Device-related infection 21.3a% [66]
Device connection issue 21.3a% [66]
Device breakage 11.9a% [66]
Unintentional removal of device by patient 10.6a% [66]
Device leakage 8.9a% [66]
Procedural site reaction 8.9a% [41]
Post procedural discharge 8.3e10.9a% [4,41,66]
Incision site pain 5.3a% [66]
Other
Abdominal pain 30.7e34.2a% [41,66] 1.5a4.7% [41,66]
Flatulence 16.2% [4]
Constipation 13.5e21.6% [4,41]
Nausea 13.5e29.7% [4,41]
Excessive granulation tissue 13.5e18.2% [41,66]
Fall 10.9% [41]
Dyskinesia 10.9% [41]
Insomnia 10.8e10.9% [4,41]
Anxiety 10.4% [41] 1.0% [41]
Headache 8.9% [41]
Diarrhea 8.3% [41]
Oropharnygeal pain 8.3% [41]
Weight decreased 8.3% [41]
Orthostatic hypotension 8.3% [41]
Dyspepsia 7.8% [41]
Urinary tract infection 7.8% [41]
Depression 7.3% [41] 1.6% [41]
Vomiting 7.3% [41]
Pneumoperitoneum 7.3e10.8% [4,41] 0.5a3.6% [41,66]
Back pain 6.8% [41] 1.0% [41]
Pain in extremity 5.7% [41]
Sleep attacks 5.7% [41]
Confusional state 5.4% [4]
Pertitonitis 1.8a3.1% [41,66]
Polyneuropathy 2.1% [41]
Hip fracture 1.6% [41]
Pneumonia 1.61.8a% [41,66]
Syncope 1.6% [41]
Radius fracture 1.0% [41]
Pyelonephritis 1.0% [41]
Small intestinal obstruction 1.0% [41]
Acute abdomen 0.5a% [66]
Gastrointestinal hemorrhage 0.5a% [66]
Paralytic ileus 0.5a% [66]
Intestinal ischemia 0.5a% [66]
Intestinal perforation 0.5a% [66]
Sepsis 0.5a% [66]
Serious adverse events are in italics.
a In patients who received a percutaneous endoscopic gastrostomy jejunal extension tube.
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infusion rate. Patients should usually be premedicated with dom-
peridone to suppress nausea and vomiting. In view of the risk of
prolonged QT interval associated with domperidone, the European
Medicines Agency recently restricted the recommended dose to a
maximum of 10 mg tid. Domperidone can often be discontinued
over subsequent days/weeks. An alternative to domperidone is oral
trimethobenzamide (300 mg tid) started 3 days before the initial
dose of SC apomorphine and continued at least during the ﬁrst
weeks of therapy. During the initiation phase, the specialist center
will usually discontinue oral dopamine agonists and gradually
reduce or discontinue the levodopa dose in patients with dyski-
nesias (with the exception of early morning and late night) in a
stepwise manner over several days to weeks. On discharge, any
further reductions in the patient's oral medication are either
explicitly recommended to the referring physician or are per-
formed at the center. If a patient is on a 12e14-h infusion, night-
time therapy may be required to avoid severe rebound phenom-
ena during the night and early morning; rotigotine transdermal
patch used overnight has been shown to be useful in this regard
[68].
LCIG infusion can be given as monotherapy at the physician's
discretion. The transfer from regular therapy to LCIG can be abrupt
(overnight) or slow over days/weeks based on the patient's con-
dition and response. Long-acting L-dopa or dopamine agonist
perorally/transdermally may be given in the evening to cover the
night if necessary. In some patients, combination with a dopamine
agonist might be beneﬁcial. Amantadine can be given additionally
for remaining troublesome dyskinesias [69]. The possible associa-
tion of LCIG infusion with an increased risk of polyneuropathy is
under investigation. Assessment of vitamin B12 levels before and
during treatment is recommended. Many centers provide vitamin
B12 substitution to all patients, although the precise indication for
vitamin B12 substitution has not been clariﬁed [70].
Management of PD patients in the longer term phase of device-
aided therapy may be overseen by the referring neurologist. Edu-
cation should be provided to neurologists to enable this re-
sponsibility. Medications can be titrated within deﬁned parameters
to address worsening or newmotor deﬁcits. For patients presenting
with sudden worsening of function, the functionality of the device
should be considered. The specialist team should be consulted
regarding adjustments to device-aided therapies and patients
should be referred to the specialist team every 6 months for review.
For patients receiving LCIG infusion therapy, referral may be as
frequent as every 3months, up to 6months after surgery, and once-
or twice-yearly thereafter.
2.10. What factors would indicate the selection of one device-aided
treatment over another?
Insufﬁcient control of motor complications (or drug-resistant
tremor [only in the case of DBS]) is the most common reason for
moving from non-invasive to device-aided therapies [71,72]; po-
tential control of some NMS may also be considered. Adverse
events and complications of non-invasive therapies can contribute
to the decision to switch to a device-related therapy. The goal of
treatment should be 24-h symptom control. Table 6 illustrates how
speciﬁc PD-related and treatment-related symptomsmay inﬂuence
the decision to use one device-aided therapy over another.
Treatment decisions should take into account symptoms,
response to optimal oral therapy, comorbidities, age, caregiver
support, and patient/caregiver preference:
 For patients aged <70 years with motor ﬂuctuations or dyski-
nesias who are otherwise healthy, any of the device-aided
therapies may be considered.
 For patients aged >70 years, DBS surgery should be considered
second-line among the device-aided therapies (although pa-
tients can be operated on in the presence of a normal MRI and
preserved cognitive function).
 For patients aged >70 years with mildly or moderately impaired
cognition (or other contraindications to DBS), LCIG infusions or
SC apomorphine may be considered with cessation or reduction
in oral therapy (note that rapid cessation of dopamine agonists
may lead to withdrawal symptoms).
3. Conclusions
The Navigate PD program was not intended to provide formal
guidance on the management of Parkinson's disease refractory to
oral/transdermal medication and cannot supplant existing national
and international guidelines. Rather, the guidance offered com-
plements existing guidelines, particularly for some areas of device-
aided management of PD not covered by existing resources or
where published evidence is lacking.
Limitations of the program include the acceptance of non-level
1 studies in the absence of comparative studies of advanced ther-
apies and consolidation of the feedback on the draft guidance to
formulate the ﬁnal guidance mainly through informal discussion
rather than formal consensus. The program design allowed incor-
poration of individual clinical experience into development of an-
swers, thus not always based on high-level evidence. However,
Table 5
Relative and absolute contraindications to device-aided therapies for the management of Parkinson's disease.a
Device-aided therapy Increasing risk Absolute contraindications
DBS  Non-compliance with non-invasive therapies
 Biological age >70e75 yearsb
 Severe depression
 Condition that increases surgical risk, including cardiomyopathy
 Lack of levodopa response, with the exception of rest tremor
 Dementia
 Severe brain atrophy or lesions interfering with trajectory planning
SC apomorphine  Non-compliance with non-invasive therapies
 MCI or dementia
 Previous or current dopamine dysregulation, punding or impulse
control disorders
 Moderate-to-severe dementia
 Lack of levodopa response
 Inability of patient and caregiver to handle medication and device
LCIG infusion  Non-compliance with non-invasive therapies
 Pre-existing peripheral neuropathiesc
 Previous or current dopamine dysregulation and punding
 Moderate-to-severe dementia
 Patient frailty (unable to support device weight)
 Lack of levodopa response
 Inability of patient and caregiver to handle medication and device
 Absolute or relative contraindications to abdominal surgery
DBS, deep brain stimulation; LCIG, levodopa-carbidopa intestinal gel; MCI, mild cognitive impairment; SC, subcutaneous.
a For a complete list of device-related absolute contraindications, the clinician is referred to the manufacturers' product information.
b Clinicians should take into account the frailty of a patient, along with other comorbidities.
c Clinician should investigate the reason for neuropathy to determine whether it is clinically relevant/symptomatic.
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feedback was obtained from>100 experts across multiple specialist
centers, which could be regarded as a strength.
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a If non-motor ﬂuctuations are present, all the device-aided treatments may be considered.
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